

*Cardiovascular diseases present the cause of more than half of all deaths in the Czech Republic. As confirmed by many clinical studies, pharmacotherapy with hypolipidemics is definitely beneficial for patients in a secondary prevention of ischemic heart disease.*

*This thesis aims to observe and compare the consumption and spectra of hypolipidemics dispensed in years 2005 and 2006 using data from a single pharmacy with specialized sites; moreover it aims to observe changes in their consumption after generic atorvastatin preparations entered the Czech market and after atorvastatin was enabled to be prescribed by general practitioners, using a month-by-month analysis of the three mostly dispensed hypolipidemics in year 2005 (atorvastatin, simvastatin and fenofibrate).*

*Using the Paenium pharmaceutical electronic system, the consumptions of individual hypolipidemic medical preparations in years 2005 and 2006 have been recorded as a number of packages actually collected by patients upon their medical prescriptions. To enable the consumptions of individual active substances and also groups of hypolipidemics to be compared, these numbers have been converted into Defined Daily Doses (DDD) and the percentage of individual active substances and groups of hypolipidemics within the total consumption have been counted.*

*According to our observations, the most dispensed active substance in year 2005 was simvastatin followed by atorvastatin and fenofibrate; in year 2006 atorvastatin took the first place (in accordance with official data presented by SÚKL), followed by simvastatin and fenofibrate. This significant increase of atorvastatin consumption may have several causes: (1) it is supported by positive conclusions of clinical studies; (2) changes in dosing and target cholesterol values may also have played their part; (3) our observation of simvastatin and atorvastatin month-by-month consumption in year 2005 confirmed the presumption that the increased atorvastatin consumption may have been caused also by the introduction of generic atorvastatin on the Czech market since April 2005 and furthermore by the release of atorvastatin for prescription by general practitioners since the second half-year 2005.*

